Cargando…

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

BACKGROUND: In trials conducted in India, recombinant granulocyte colony stimulating factor (GCSF) improved survival in alcohol-associated hepatitis (AH). The aim of this trial was to determine the safety and efficacy of pegfilgrastim, a long-acting recombinant GCSF, in patients with AH in the Unite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tayek, John A., Stolz, Andrew A., Nguyen, Danh V., Fleischman, M. Wayne, Donovan, John A., Alcorn, Joseph M., Chao, Daniel C-K., Asghar, Aliya, Morgan, Timothy R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576807/ https://www.ncbi.nlm.nih.gov/pubmed/36267499 http://dx.doi.org/10.1016/j.eclinm.2022.101689

Ejemplares similares

Differentiating between liver diseases by applying multiclass machine learning approaches to transcriptomics of liver tissue or blood-based samples
por: Listopad, Stanislav, et al.
Publicado: (2022)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
por: Lee, Anbok, et al.
Publicado: (2023)

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan
por: Kosaka, Takeo, et al.
Publicado: (2019)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma
por: Cerchione, Claudio, et al.
Publicado: (2022)

Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies
por: Civoli, Francesca, et al.
Publicado: (2022)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
por: Link, Hartmut, et al.
Publicado: (2020)

Importance of fasting blood glucose goals in the management of type 2 diabetes mellitus: a review of the literature and a critical appraisal
por: Tayek, Chandler J, et al.
Publicado: (2018)

Relapsing Acute Kidney Injury Associated with Pegfilgrastim
por: Arora, Swati, et al.
Publicado: (2012)

Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2013)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
por: Kang, Ka‐Won, et al.
Publicado: (2020)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Cyclophosphamide/docetaxel/pegfilgrastim: Various toxicities: case report
Publicado: (2021)

Evaluation of a novel medical device for pegfilgrastim administration
por: Aruga, Tomoyuki, et al.
Publicado: (2022)

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial
por: Wynne, Chris, et al.
Publicado: (2020)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study
por: Kowalyszyn, Ruben D., et al.
Publicado: (2022)

Initial testing of pegfilgrastim (Neulasta Onpro) on‐body injector in multiple radiological imaging environments
por: Long, Zaiyang, et al.
Publicado: (2021)

A Multicenter, Randomized, Open-Labeled, Parallel Group Trial of Sildenafil in Alcohol-Associated Erectile Dysfunction: The Impact on Psychosocial Outcomes
por: Ponizovsky, Alexander M., et al.
Publicado: (2009)

Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma
por: Cocorocchio, E, et al.
Publicado: (2010)

Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma
por: Hatayama, Mayumi, et al.
Publicado: (2018)

Neutrophilic eccrine hidradenitis secondary to pegfilgrastim in a patient with synovial sarcoma
por: Puar, Neha, et al.
Publicado: (2019)

Pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
por: Wessels, Hendrik, et al.
Publicado: (2019)

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
por: Brekkan, Ari, et al.
Publicado: (2019)

Open Label Trial of the Tolerability and Efficacy of Zonisamide in the Treatment of Alcohol Dependence
por: Knapp, Clifford M., et al.
Publicado: (2010)

High-flow nasal oxygen for suspension laryngoscopy: a multicenter open-label study
por: Saad, Mary, et al.
Publicado: (2022)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
por: Bondarenko, Igor, et al.
Publicado: (2013)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy
por: Li, Yanli, et al.
Publicado: (2016)

The ELISA Detectability and Potency of Pegfilgrastim Decrease in Physiological Conditions: Key Roles for Aggregation and Individual Variability
por: Xie, Tao, et al.
Publicado: (2020)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
por: Roth, Karsten, et al.
Publicado: (2019)

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
por: Cornes, Paul, et al.
Publicado: (2020)

Recurrent Granulocyte Colony-Stimulating Factor-Induced Aortitis After Pegfilgrastim Administration
por: Kawahara, Hiroshi, et al.
Publicado: (2020)

Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report
por: Jimbo, Hikari, et al.
Publicado: (2021)

A Case of Concurrent Leukocytosis and Systemic Capillary Leak Syndrome Due to Pegfilgrastim
por: Gotera, Nico, et al.
Publicado: (2022)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
por: Rastogi, Shruti, et al.
Publicado: (2022)

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
por: Jeon, Youngwoo, et al.
Publicado: (2023)

An Open-Label, Multicenter Observational Study for Patients with Alzheimer's Disease Treated with Memantine in the Clinical Practice
por: Stamouli, S.S., et al.
Publicado: (2011)

PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta(®)): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
por: Moosavi, Shahrzad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9l0kk2aondjvoa8epoqa0194hk